Report sees opportunities in Filipino pharma market which will be worth $4.1 billion by 2020

2 September 2016

The pharmaceutical market in the Philippines will rise from its $3.4 billion value in 2015 to $4.1 billion by 2020, at a compound annual growth rate of 3.7%.

That is the prediction of research and consulting firm GlobalData in its report on pharma in the country, which is the third-largest in the Association of Southeast Nations, behind Indonesia and Thailand.

The report expects that over the next four years, the market will be characterized by government encouragement of generic substitution in the public and private sectors, and strong patent and trademark laws to help protect innovation and encourage foreign investment in health care.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK